Amphastar Pharmaceuticals Inc
AMPH
ISIN null / Valor 24511852
Amphastar Pharmaceuticals Inc
UMushroom community rating:
About company
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development, manufacturing, and marketing of pharmaceutical products. The company is dedicated to providing high-quality medications to improve patient outcomes and enhance overall healthcare. With a focus on innovation and research, Amphastar Pharmaceuticals Inc strives to bring new and effective treatments to market to address a wide range of medical conditions.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (12.10.2025):
Amphastar Pharmaceuticals Inc. reported its financial results for the second quarter of 2025, showcasing a 4% decrease in net revenues compared to the same period last year. Despite the overall revenue decline, the company experienced significant growth in its BAQSIMI® product line, which became a major revenue driver. However, sales of other key products like Epinephrine and Glucagon saw decreases, impacting the overall financial performance.
Net Revenues Decline
For the three months ended June 30, 2025, Amphastar Pharmaceuticals Inc. reported net revenues of $174.4 million, a 4% decrease from $182.4 million in the second quarter of 2024. This decline was primarily influenced by reduced sales in several product categories.
BAQSIMI® Sales Surge
The company's BAQSIMI® product experienced robust growth, with total sales increasing by 51% to $46.7 million compared to $30.9 million in the same quarter last year. This strong performance solidified BAQSIMI® as a key revenue driver for Amphastar in 2025.
Decline in Epinephrine and Glucagon Sales
Sales of Epinephrine decreased by 42% to $16.2 million, while Glucagon sales dropped by 25% to $20.6 million. These declines were attributed to increased competition and a shift towards ready-to-use formulations, which affected unit volumes and average selling prices.
Increase in Operating Expenses
Operating expenses rose by 14% in selling, distribution, and marketing, reaching $10.2 million from $9.0 million in the previous year. Additionally, research and development expenses increased by 14% to $20.1 million, driven by higher material costs and expanded clinical trials.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1204 M
Market cap (USD)
484,851
Daily traded volume (Shares)
37.69 / 36.83
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
